May 14, 2020
FDA accelerates development of COVID-19 prevention, treatment options
Editor's Note
The Food & Drug Administration on May 11 took new actions to accelerate the development of novel prevention and treatment options for COVID-19.
The agency is providing guidance documents to make the process for submitting applications to initiate studies for new drugs and biological products more efficient.
The documents also outline recommendations for ways to design clinical trials to evaluate safety and effectiveness of these products for COVID-19.
Free Daily News
- Kentucky Derby, SPD race: Leadership lessons energized SPD professionals at HSPA 2025
- Continuum-based protocol offers new strategy for preventing PONV after thyroidectomy
- Pembrolizumab sets new standard in advanced head and neck cancer surgery, trial shows
- Subarachnoid spinal anesthesia offers safe, effective option for high-risk obstetric patients
- Same-day discharge after catheter ablation gains backing from top cardiology societies
- Tenet, HCA post strong Q1 results, but caution looms over policy uncertainty, outpatient trends
- Telemedicine transforms postoperative care through safer, faster, patient-centered recovery
- ASCA conference coverage to keep ASC leaders informed
- Study: Prolonged COVID symptoms more likely for healthcare workers
- Study: Patients of female surgeons experience fewer complications, lower long-term readmission
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement